由 sufang 在 六, 11/22/2014 – 09:01 發表 Cholangiocarcinoma cholangiocarcinoma FFPE Gene Fusion Nov 5 2014 Daw-yang Hwang 黃道揚 to LTCHEN, yngmiin Dear Prof Lin, Dr. Chiang, and SF: I designed primers for ALK, ROS-1 FGFR2, FGFR3, and I can add primers for RET.In my research part (bladder and upper urinary tract cancer), I am collaborating […]
Fusion gene detection Read More »
由 sufang 在 四, 11/20/2014 – 12:53 發表 EBV and KSHV CTCF Mol Cell Biol. 2014 Oct;34(20):3867-79. doi: 10.1128/MCB.00567-14. Epub 2014 Aug 18.CTCF controls HOXA cluster silencing and mediates PRC2-repressive higher-order chromatin structure in NT2/D1 cells.Xu M1, Zhao GN1, Lv X1, Liu G1, Wang LY2, Hao DL1, Wang J3, Liu DP4, Liang CC1.Author informationAbstract HOX
由 sufang 在 四, 11/20/2014 – 13:20 發表 Pre-published IDO1 KYN Remarkable Role of Indoleamine 2,3-Dioxygenase and Tryptophan Metabolites in Infectious Diseases: Potential Role in Macrophage-Mediated Inflammatory Diseases (PubMed) (pdf 4235) Figure 1. Schematic overview of the kynurenine pathway. It is estimated that only 1% of dietary tryptophan (TRP) can be converted into serotonin (5-HT). The
Remarkable Role of Indoleamine 2,3-Dioxygenase and Tryptophan Metabolites Read More »
#1由 sufang 在 一, 05/18/2015 – 08:50 發表。 Keratinocyte culture method 說在前面: Rheinwald Lab所寄給我們的Human Keratinocyte Culture Methods第一段便比較下面三個廠商來的media, 說請大家用K-sfm來養”low-to-moderate density”的keratinocytes (primary or immortalized) K-sfm Life Technologies grow well from low to moderate density EpiLife Life Technologies KGM (or MCDB154) Clonetics very short replicative lifespan 第二段: 須牢記於心的是, K-sfm的營養成分僅適用於低密度、聚集性的keratinocyte生長, 因此用K-sfm養的細胞, 1/3滿度前就必須passage. 第三段: 碰到OSCC的話, 建議與irradiated 3T3
Protocols-including KDF Read More »
由 sufang 在 二, 11/18/2014 – 15:13 發表 Pre-published CXCL 素菁 ID 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 CXCL1 4.89 5.66 2.24 0.9 1 0.9 2.33 3.67 2.1 4.45 1.17 9.2 1.06 7.18 1.29 1.7 3.57 2.51 1.29 0.58
Cloning of colorful CXCL1, 2, 3, IDO1, TDO2 Read More »
DDR1 manuscript 相關 由 sufang 在 五, 11/07/2014 – 16:57 發表 Pre-published CDDis DDR1 Front Oncology manuscript 2015/05/08 (Thu) MS submitted to Research Topic “Oral Oncology” 2015/05/30 (Sat) MS returned, interactive reviews activated: Editor: Rui Amaral Mendes Catholic University of Portugal; Editor of J Carcinogenesis and Mutagenesis; Adhuant Prof at CWRU 2015/08/28 rejected… by Specialty Chief
DDR1 manuscript 相關 Read More »
Dear All, I like to invite you to join two exciting Epigenetic Talks by the world leading scientists Yi Zhang and Bing Ren on Oct 23 and Nov 4, respectively, at Academia Sinica. Bing Ren UCSD Regulation of the 3D Genome 11 am, Nov 4, 2014 B1 Auditorium, IMB, Academia Sinica Dr. Bing Ren, Member of Ludwig
Epigenetic Talks Bing Ren Read More »
由 sufang 在 日, 11/02/2014 – 11:09 發表 Pre-published Cancer Metabolism Notes Youtube https://www.youtube.com/watch?v=nFelWNxpdWk Genomic alterations in cancersmutations (300,000; > 20,000 genes)epithelial : 50-100; leukemia: 20amplifications (3000)deletions (thousands)translocations (fusions: 7000)epigenetic changes (extensive)Drivers : hundred, 90% loss of functionsInter-and intra-tumor heterogeneity (Charles Sweton)< 1/2 mutated or amplified genes expressed Two more oncometabolic papers from Harvard Groups: Nature (2011). Functional
2014年10月30日癌症研究國際研討會: 從基礎科學到臨床應用 由 sufang 在 四, 10/30/2014 – 09:42 發表 Pre-published cancer of excellence International symposium on cancer research Meeting 二期癌症研究計劃 癌症研究國際研討會 衛福部 首頁: http://scr.nhri.org.tw/index.jsp 台大醫院國際會議中心 301會議室 (77240109) 衛福部 許明能次長致辭 龔院長致辭 1. 張元吉教授: Combination targeted therapy in advanced lung cancer 2. 陳慶士教授: Fighting an organized crime network in pancreatic cancer: tumor
2014年10月30日癌症研究國際研討會: 從基礎科學到臨床應用 Read More »
由 sufang 在 二, 10/28/2014 – 14:27 發表 Pre-published EBV EBV associated gastric cancer IDO1 Lymphoproliferative disorders PLoS Pathog. 2013;9(5):e1003341. doi: 10.1371/journal.ppat.1003341. Epub 2013 May 9.Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy. Strong MJ1, Xu G, Coco J, Baribault C, Vinay DS, Lacey MR, Strong
EBV associated malignancies and IDO1 expression Read More »